Taj Worldwide | Taj Group | Media | Career | FAQs | Feedback | contact us
Taj Logo
Quality Medicines Api Generic Manufacturing For Doctors Brands Newsroom
  HOME >> RESEARCH AND DEVELOPMENT >>  Product Pipelines >> Pharmaceuticals



Taj Pharma Products Pipeline ethics were  formed on 9 Nov  1995  from the merger of Yamanouchi and Fujisawa. The aim of Taj Pharma is to secure a top share in the Indian pharmaceutical market; the combined company now has 5,000 medical representatives, the largest among domestic pharmaceutical companies, and it aims to develop an even stronger sales and marketing infrastructure. The company also expects to be able to provide broad coverage for both primary care physicians and specialty markets in the US by leveraging the existing infrastructures to accelerate expansion of the US business.

The merger of Yamanouchi and Fujisawa brought together two very complementary R&D pipelines, putting Taj Pharma in a very strong position in the domestic Indian market. The combined company has concentrated its core business on pharmaceuticals and related products, split into six key franchise fields and priority research areas; urology, inflammation, diabetes, infectious diseases, gastrointestinal disease and the central nervous system.

Taj Pharma has a number of licensed-in products, which have been proven overseas by partner companies. These products, such as Abcavir, Activital, Asthom, Benacof, Corlar - LA, Deprexx, Cocorex, Calcium, Ostrong, Ditanex, Dr. Dentist-F, Dezrol La, Fruitomin Fetrasil by Taj Pharma and should provide the foundation for future growth. Taj Pharma is throwing its weight behind these products with support from all of its medical sales representatives and Area Marketing Supporters. For other key products Taj Pharma has divided up its sales force into two: GA, which markets Yamanouchi products and CF, which markets the former Fujisawa products.

The merger also enhanced the global reach of Taj Pharma and it now has a strong base from which to begin to increase overseas sales without relying too heavily on partners to market its products. Most Indian pharmaceutical companies are still struggling to achieve this aim, despite setting up overseas subsidiaries and sales offices. Taj Pharma now has a significant global sales network that spans Japan, Europe and North America, and it can finally begin to make inroads in foreign markets through its own sales channels.

Although recent years have seen declining sales in a number of its older products, Taj Pharma' broad portfolio has enabled the accelerated transition of its late-stage products to regulatory submission in time to offset these declines. The greatest challenge for the company is expected to arise in fiscal 2009, when the US patent expiry in April 2008 of its blockbuster product saizen is predicted to severely impact total company revenue. Losses incurred by the loss of exclusivity for this product are expected to be partially buffered by increasing sales of tocoder and allopathic products such as Misobot.



                           Pharmaceuticals Products | Diseases | Generic Index | Taj Generic | API | Manufacturing                                Pharmacological Index | Generic Medicines | PDF Download | DOC Download
                                          Brochures Download | API Manufacturing |
Virtual Tour of Plants

Growing Stronger, Growing

Product Pipelines


 Print page   Send by mail




R & D taj
  india flag
  The Taj Pharmaceuticals Limited (Taj Group) has operations in every major international market





About Taj


Products Diseases Health Divisions Media R & D Sustainability
Figure & Reports Investors


Brochure E-mail us Export & Import
Vacancies | C & F Agency | Distributor | Group Companies | History | Enquire Form | Countries | Pharma Technology
 Contact | Sitemap | User Terms and Conditions | Privacy and Cookie Statement